Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut
27/02/2026 17:53
Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' GENB.O shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings. (Reporting by Pragyan Kalita in Bengaluru; Editing by Sahal Muhammed) ((Pragyan.Kalita@thomsonreuters.com;))
Recent news on Amgen
See all newsFactbox: Global drugmakers invest billions to boost US presence
China's Harbour BioMed to focus on another patent case after $20 million damages award
Amgen owes $20.2 million in antibody patent lawsuit, US jury says (updated)
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says
Amgen taps research firm to reassess Tavneos data (updated)